admin – page 3 – eisai china lnc.-威尼斯人888

abbvie gk (headquarters: minato-ku, tokyo; president: james feliciano, hereafter “abbvie”) and eisai co., ltd. (headquarters: tokyo; ceo: haruo naito, hereafter “eisai”) today announced an approval of additional indication of humira® (generic name: adalimumab [recombinant], hereafter “humira”), a fully human anti-tnfα monoclonal antibody, for the treatment of pyoderma gangrenosum (hereafter “pg”). humira was granted orphan drug designation for the treatment of pg in 2019. this indication counts for humira’s 12th indication in japan and makes humira the world’s first drug indicated for the treatment of pg.

gilead sciences k.k. (head office: chiyoda-ku, tokyo; president and representative director: luc hermans; “gilead”) and eisai co., ltd. (head office: bunkyo-ku, tokyo, ceo: haruo naito; “eisai”) today announced that jyseleca® (filgotinib maleate 200 mg and 100 mg tablets), a new once-daily, oral, jak (janus kinase) inhibitor that preferentially inhibits jak1, will be launched in japan on november 18 for the treatment of rheumatoid arthritis (ra), with prior regulatory approval by the japanese ministry of health, labour and welfare.